http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110590602-B

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C253-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C253-30
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C253-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C253-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-59
filingDate 2019-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2022-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2022-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-110590602-B
titleOfInvention Resolution refining method of racemic citalopram diol
abstract The invention discloses a resolution and refining method of racemic citalopram diol, which comprises the following steps: carrying out dissolving-crystallization operation on racemic citalopram diol and a resolving agent by alternately using a solvent A and a solvent B, and respectively collecting (S) -citalopram diol salt and (R) -citalopram diol salt obtained by crystallization each time; the (S) -citalopram diol salt and the (R) -citalopram diol salt collected each time were combined separately and further refined to give (S) -citalopram diol salt and (R) -citalopram diol salt. The method uses less than the theoretical use amount of the resolving agent, and achieves the effect of resolving (S) -citalopram diol reported in literatures. The (R) -citalopram dialkoxide is conveniently recycled by changing the solvent, and the discharge amount of three wastes is reduced.
priorityDate 2019-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006106531-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507269
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31272
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538408
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8051
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6101829
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490850
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID447315
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID146570
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493337
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450274342
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490743
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6584
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419516083
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419525872
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419513958
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7997
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8857
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3776
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419523117
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87130052
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2771
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419575380

Total number of triples: 40.